Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

OBJECTIVES: More and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunotherapy is still a controversy for NSCLC patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Chen, Ya, Yang, Zhengyu, Wang, Yanan, Hu, Minjuan, Zhang, Bo, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Han, Baohui
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085497/
https://ncbi.nlm.nih.gov/pubmed/33937084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.671228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados